By Josh White
Date: Monday 01 Sep 2025
(Sharecast News) - Crism Therapeutics said on Monday that it has received both regulatory clearance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and ethical approval from a UK Research Ethics Committee to begin its registration-grade phase two trial of irinotecan-ChemoSeed in glioblastoma patients.
Net Asset Value(s) | 12-Sep-2025 | 18:00 | RNS |
Net Asset Value(s) | 12-Sep-2025 | 16:43 | RNS |
Net Asset Value(s) | 12-Sep-2025 | 15:21 | RNS |
Notice of General Meeting | 12-Sep-2025 | 10:00 | RNS |
Net Asset Value(s) | 12-Sep-2025 | 09:19 | RNS |
Squeeze sees Blackstone ditch acquisition | 02-Jan-2008 | Telegraph |
Bhutto assassination hits world markets | 31-Dec-2007 | Guardian |
Small Talk: Stockwell offers small investors a s... | 22-Jan-2007 | The Independent |
No recent information was found.
Price | 0.00 |
Closing Price Change | 0.00 |
% Change | 0.00 % |
--25 Close | 0.00 |
You are here: research